Recombinant Human IL-7-HYFC Uses, Dosage, Side Effects and more
Recombinant Human IL-7-HYFC (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response. Compared to endogenous IL-7, NT-I7 is more stable and potent, has a longer half-life, and has better bioavailability. This drug is currently being investigated in the areas of oncology, immunology, and infectious disease.
| Attribute | Details |
|---|---|
| Trade Name | Recombinant Human IL-7-HYFC |
| Generic | Efineptakin alfa |
| Efineptakin alfa Other Names | Efineptakin alfa, Hyleukin, NT-I7, Recombinant human IL-7-HYFC |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
